Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats
Denise van der Graaff(University of Antwerp), Sven Francque(University of Antwerp), Michiel D'Hondt(University of Antwerp), Benedicte Y. De Winter(University of Antwerp), Wim Verlinden(University of Antwerp), F Couturier(University of Antwerp), Isabel Brosius(University of Antwerp), P. Michielsen(University of Antwerp), Ann Driessen(University of Antwerp), Joris G. De Man(University of Antwerp), Jesse S Govaerts(University of Antwerp), Wilhelmus J. Kwanten(Antwerp University Hospital)
Cited by 47
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789